GSK plc(GSK)Earnings, Financials & Key Ratios

GSK•NYSE

$50.38

$101.32B mkt cap·6.7× P/E·Price updated May 6, 2026

SectorHealthcare IndustryLarge Pharma Sub-IndustryVaccines and plasma-derived therapies

AboutGSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.Show more

Revenue$32.67B+4.1%
EBITDA$10.65B+62.1%
Net Income$5.72B+122.0%
EPS (Diluted)5.56+348.4%
Gross Margin72.4%+1.7%
EBITDA Margin32.61%+55.7%
Operating Margin25.52%+99.2%
Net Margin17.5%+113.2%
ROE39.4%+124.9%
ROIC22.1%+126.8%
Debt/Equity1.11-14.4%
Interest Coverage11.77+88.0%

Analysis→Technical→

GSK Key Insights

GSK plc (GSK) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Excellent 3Y average ROE of 31.4%
✓Strong Piotroski F-Score: 8/9
✓FCF machine: 17.8% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Share count reduced 50.3% through buybacks
✓Healthy 5Y average net margin of 22.1%

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

GSK Price & Volume

GSK plc (GSK) stock price & volume — 10-year historical chart

Loading chart...

GSK Growth Metrics

GSK plc (GSK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years3.16%

5 Years6.05%

3 Years3.66%

TTM5.41%

Profit CAGR

10 Years-3.8%

5 Years-0.12%

3 Years-27.43%

TTM86.94%

EPS CAGR

10 Years2.6%

5 Years14.22%

3 Years32.32%

TTM120.34%

Return on Capital

10 Years11.92%

5 Years12.74%

3 Years15.54%

Last Year21.54%

GSK Recent Earnings

GSK plc (GSK) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 10/12 qtrs (91%)●Beat Revenue 10/12 qtrs (91%)

Q2 2026Latest

Apr 29, 2026

EPS

$1.24

Est $1.16

+6.9%

Revenue

$10.3B

Est $10.2B

+0.7%

Q1 2026

Feb 4, 2026

EPS

$0.68

Est $0.64

+6.3%

Revenue

$11.8B

Est $11.4B

+3.2%

Q4 2025

Oct 29, 2025

EPS

$1.48

Est $1.26

+17.5%

Revenue

$8.5B

Est $8.5B

+0.8%

Q3 2025

Jul 30, 2025

EPS

$0.96

Revenue

$10.9B

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Apr 29, 2026	$1.24vs $1.16+6.9%	$10.3Bvs $10.2B+0.7%
Q1 2026	Feb 4, 2026	$0.68vs $0.64+6.3%	$11.8Bvs $11.4B+3.2%
Q4 2025	Oct 29, 2025	$1.48vs $1.26+17.5%	$8.5Bvs $8.5B+0.8%
Q3 2025	Jul 30, 2025	$0.96	$10.9B

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
AZNAstraZeneca PLCDirect Competitor	280.97B	181.24	27.71	8.63%	17.19%	22.24%	4.19%	0.61
NVSNovartis AGDirect Competitor	277.63B	145.50	20.24	5.97%	24.14%	31.42%	6.37%	0.80
SNYSanofiDirect Competitor	104.72B	43.36	18.20	5.49%	16.72%	10.78%	9.97%	0.30
PFEPfizer Inc.Direct Competitor	150.4B	26.44	19.44	-1.65%	11.83%	8.34%	6.03%	0.78
MRKMerck & Co., Inc.Direct Competitor	279.49B	113.16	15.54	1.18%	28.12%	36.14%	4.42%	0.96
BMYBristol-Myers Squibb CompanyDirect Competitor	116.22B	56.92	16.50	-0.22%	15.01%	38.96%	11.05%	2.55
LLYEli Lilly and CompanyDirect Competitor	933.66B	988.19	43.06	44.7%	34.98%	101.17%	0.96%	1.60
ABBVAbbVie Inc.Product Competitor	364.63B	206.15	86.98	8.57%	6.91%	62.15%	4.89%

Compare GSK vs Peers

GSK plc (GSK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs AZN

Most directly comparable listed peer for GSK.

Scale Benchmark

vs LLY

Larger-name benchmark to compare GSK against a more recognizable public peer.

Peer Set

Compare Top 5

vs AZN, NVS, SNY, PFE

GSK Income Statement

GSK plc (GSK) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	30.19B	30.82B	33.75B	24.35B	24.7B	29.32B	30.33B	31.38B	32.67B	33.34B
Revenue Growth %	8.24%	2.1%	9.52%	-27.85%	1.4%	18.74%	3.42%	3.46%	4.11%	5.41%
Cost of Goods Sold	10.34B	10.24B	11.86B	7.93B	8.16B	9.55B	8.56B	9.05B	9.02B	8.96B
COGS % of Revenue	34.26%	33.23%	35.15%	32.56%	33.05%	32.58%	28.24%	28.84%	27.6%	-
Gross Profit	19.84B▲ 0%	20.58B▲ 3.7%	21.89B▲ 6.4%	16.43B▼ 25.0%	16.53B▲ 0.7%	19.77B▲ 19.6%	21.76B▲ 10.1%	22.33B▲ 2.6%	23.65B▲ 5.9%	24.29B▲ 0%
Gross Margin %	65.74%	66.77%	64.85%	67.44%	66.95%	67.42%	71.76%	71.16%	72.4%	72.86%
Gross Profit Growth %	6.69%	3.71%	6.37%	-24.97%	0.66%	19.58%	10.08%	2.6%	5.92%	-
Operating Expenses	15.76B	15.1B	14.93B	10.45B	12.18B	13.34B	15.02B	18.31B	15.31B	15.41B
OpEx % of Revenue	52.2%	48.98%	44.23%	42.89%	49.3%	45.48%	49.52%	58.35%	46.87%	-
Selling, General & Admin	9.67B	9.91B	11.4B	7.44B	7.07B	8.37B	9.38B	11.02B	9.09B	9.14B
SG&A % of Revenue	32.04%	32.17%	33.78%	30.54%	28.63%	28.55%	30.95%	35.11%	27.82%	-
Research & Development	4.48B	3.89B	4.57B	4.79B	5.02B	5.49B	6.22B	6.4B	7.53B	7.75B
R&D % of Revenue	14.83%	12.63%	13.53%	19.68%	20.32%	18.71%	20.52%	20.4%	23.04%	-
Other Operating Expenses	1.61B	1.29B	-1.04B	-1.78B	87M	-523M	-590M	891M	-1.3B	-4M
Operating Income	4.09B▲ 0%	5.48B▲ 34.2%	6.96B▲ 27.0%	5.98B▼ 14.1%	4.36B▼ 27.1%	6.43B▲ 47.6%	6.75B▲ 4.8%	4.02B▼ 40.4%	8.34B▲ 107.4%	8.98B▲ 0%
Operating Margin %	13.54%	17.79%	20.62%	24.55%	17.64%	21.94%	22.24%	12.82%	25.52%	26.95%
Operating Income Growth %	57.31%	34.16%	26.96%	-14.11%	-27.13%	47.65%	4.85%	-40.39%	107.36%	-
EBITDA	6.01B	7.34B	9.08B	8.03B	6.48B	8.58B	9.04B	6.57B	10.65B	11.71B
EBITDA Margin %	19.91%	23.81%	26.9%	32.97%	26.24%	29.26%	29.8%	20.95%	32.61%	35.11%
EBITDA Growth %	37.44%	22.13%	23.74%	-11.58%	-19.3%	32.43%	5.35%	-27.29%	62.08%	38.23%
D&A (Non-Cash Add-back)	1.92B	1.86B	2.12B	2.05B	2.12B	2.15B	2.29B	2.55B	2.31B	3.14B
EBIT	4.26B	5.49B	7.1B	6.02B	4.36B	6.45B	6.79B	4.12B	8.09B	8.13B
Net Interest Income	-667M	-665.8M	-810.89M	-852M	-755M	-791.26M	-735M	-590.19M	-631M	-601M
Interest Income	65M	77.83M	98M	44M	28M	64.27M	40M	67.39M	56M	98M
Interest Expense	734M	743.64M	912M	892M	784M	855.53M	775M	657.58M	687M	692M
Other Income/Expense	-562M	-683M	-740M	-809M	-758M	-805M	-681M	-544M	-937M	-978M
Pretax Income	3.52B▲ 0%	4.8B▲ 36.2%	6.22B▲ 29.6%	5.17B▼ 16.9%	3.6B▼ 30.4%	5.63B▲ 56.4%	6.06B▲ 7.7%	3.48B▼ 42.7%	7.4B▲ 112.9%	7.44B▲ 0%
Pretax Margin %	11.68%	15.57%	18.43%	21.23%	14.57%	19.19%	19.99%	11.08%	22.66%	22.31%
Income Tax	1.36B	754M	953M	67M	83M	707M	756M	526M	1.11B	1.08B
Effective Tax Rate %	38.47%	15.71%	15.32%	1.3%	2.31%	12.56%	12.47%	15.13%	15.02%	14.54%
Net Income	1.53B▲ 0%	3.62B▲ 136.5%	4.64B▲ 28.2%	5.75B▲ 23.8%	4.38B▼ 23.7%	14.96B▲ 241.1%	4.93B▼ 67.1%	2.58B▼ 47.7%	5.72B▲ 122.0%	6.4B▲ 0%
Net Margin %	5.08%	11.76%	13.76%	23.61%	17.76%	51%	16.25%	8.21%	17.5%	19.19%
Net Income Growth %	67.98%	136.49%	28.21%	23.77%	-23.73%	241.07%	-67.05%	-47.75%	121.98%	86.94%
Net Income (Continuing)	2.17B	4.05B	5.27B	5.1B	3.52B	4.92B	5.31B	2.95B	6.29B	6.36B
Discontinued Operations	0	0	0	1.28B	1.58B	10.7B	0	0	0	0
Minority Interest	3.56B	-688M	9.21B	8.5B	8.52B	-502M	-703.69M	-585M	-420.26M	-567.04M
EPS (Diluted)	0.78▲ 0%	1.82▲ 133.3%	2.32▲ 27.5%	2.86▲ 23.3%	2.70▼ 5.6%	2.40▼ 11.1%	2.40▲ 0.0%	1.24▼ 48.3%	5.56▲ 348.4%	3.14▲ 0%
EPS Growth %	69.57%	133.33%	27.47%	23.28%	-5.59%	-11.11%	0%	-48.33%	348.39%	120.34%
EPS (Basic)	0.78	1.84	2.34	2.88	2.74	2.44	2.44	1.26	5.64	-
Diluted Shares Outstanding	1.98B	1.99B	2.01B	2.02B	1.62B	2.04B	2.06B	2.07B	1.03B	2.04B
Basic Shares Outstanding	1.95B	1.97B	1.98B	1.99B	1.6B	2.01B	2.03B	2.04B	1.01B	2.01B
Dividend Payout Ratio	254.96%	108.39%	85.1%	69.18%	91.2%	28.55%	56.68%	94.91%	43.87%	-

GSK Balance Sheet

GSK plc (GSK) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	15.91B	16.93B	25.82B	27.68B	25.29B	20.77B	23.77B	17B	17.48B	23.42B
Cash & Short-Term Investments	3.91B	3.96B	6.34B	8.71B	5.87B	7.88B	6.61B	3.71B	3.4B	4.54B
Cash Only	3.83B	3.87B	6.24B	8.6B	5.79B	3.72B	3.74B	3.69B	3.39B	4.54B
Short-Term Investments	78M	84M	104.66M	106.62M	82.62M	4.15B	2.86B	21M	8.98M	1.32M
Accounts Receivable	5.69B	6.32B	9.47B	9.93B	10.88B	6.22B	9.44B	6B	7.75B	10.47B
Days Sales Outstanding	68.83	74.87	102.4	148.82	160.77	77.4	113.58	69.79	86.54	109.31
Inventory	5.56B	5.48B	7.88B	8.2B	7.83B	5.15B	7.01B	5.67B	5.91B	8.12B
Days Inventory Outstanding	196.12	195.17	242.4	377.3	350.23	196.6	298.68	228.69	239.38	311.71
Other Current Assets	1.4B	841M	1.71B	352.67M	284.43M	1.1B	262.61M	1.23B	420.26M	295.39M
Total Non-Current Assets	40.47B	41.14B	79.75B	82.27B	81.85B	39.38B	51.45B	42.47B	43.53B	59.48B
Property, Plant & Equipment	10.86B	11.06B	14.99B	15.04B	14.45B	9.62B	12.69B	10.07B	10.03B	13.24B
Fixed Asset Turnover	2.78x	2.79x	2.25x	1.62x	1.71x	3.05x	2.39x	3.11x	3.26x	2.64x
Goodwill	5.73B	5.79B	13.99B	14.49B	14.29B	7.05B	8.68B	6.98B	7.01B	9.61B
Intangible Assets	17.56B	17.2B	41.01B	40.77B	40.74B	14.32B	18.83B	15.52B	16.72B	23.92B
Long-Term Investments	1.02B	1.47B	3.18B	4.83B	4.29B	-2.61B	2.73B	1.21B	1.12B	5.21B
Other Non-Current Assets	1.5B	1.73B	1.15B	1.28B	1B	5.35B	808.22M	1.93B	2.14B	10.87B
Total Assets	56.38B▲ 0%	58.07B▲ 3.0%	105.57B▲ 81.8%	109.95B▲ 4.1%	107.14B▼ 2.6%	60.15B▼ 43.9%	75.22B▲ 25.1%	59.46B▼ 20.9%	61.01B▲ 2.6%	82.91B▲ 0%
Asset Turnover	0.54x	0.53x	0.32x	0.22x	0.23x	0.49x	0.40x	0.53x	0.54x	0.43x
Asset Growth %	-4.57%	2.99%	81.81%	4.14%	-2.55%	-43.86%	25.06%	-20.95%	2.6%	61.3%
Total Current Liabilities	26.57B	22.49B	31.86B	30.28B	32.06B	22.81B	26.86B	21.7B	21.35B	29.58B
Accounts Payable	3.53B	3.65B	5.49B	5.96B	6.14B	3.87B	4.74B	3.46B	15.35B	18.9B
Days Payables Outstanding	124.51	129.91	168.91	274.17	274.65	147.7	201.93	139.66	621.51	715.75
Short-Term Debt	2.8B	5.77B	9.16B	5.09B	4.88B	3.79B	3.59B	2.18B	3.01B	6.65B
Deferred Revenue (Current)	1.7B	1.82B	209.31M	493.47M	415.82M	0	283.01M	0	0	0
Other Current Liabilities	12.68B	10.52B	14.22B	16.03B	17.97B	14.1B	15.25B	14.76B	2.5B	3.29B
Current Ratio	0.60x	0.75x	0.81x	0.91x	0.79x	0.91x	0.88x	0.78x	0.82x	0.82x
Quick Ratio	0.39x	0.51x	0.56x	0.64x	0.54x	0.68x	0.62x	0.52x	0.54x	0.54x
Cash Conversion Cycle	140.44	140.13	175.89	251.95	236.35	126.3	210.33	158.82	-295.6	-294.73
Total Non-Current Liabilities	26.32B	31.9B	49.39B	51.23B	46.17B	27.24B	32.05B	24.68B	23.66B	30.35B
Long-Term Debt	14.22B	20.23B	29.91B	30.81B	26.76B	16.19B	18.04B	13.7B	14.68B	18.48B
Capital Lease Obligations	43M	44M	1.34B	1.21B	1.1B	841M	1.34B	934M	0	0
Deferred Tax Liabilities	1.4B	1.16B	5.05B	4.92B	4.82B	289M	396.46M	382M	290.49M	1.73B
Other Non-Current Liabilities	10.56B	10.46B	13.06B	14.26B	13.38B	9.83B	11.95B	9.5B	8.69B	44.37B
Total Liabilities	52.89B	54.39B	81.25B	81.5B	78.23B	50.05B	58.91B	46.38B	45.02B	59.93B
Total Debt	17.09B	26.06B	40.42B	37.11B	32.74B	20.99B	22.97B	16.99B	17.69B	25.13B
Net Debt	13.26B	22.19B	34.18B	28.51B	26.95B	17.26B	19.23B	13.29B	14.3B	20.59B
Debt / Equity	4.90x	7.10x	1.66x	1.30x	1.13x	2.08x	1.41x	1.30x	1.11x	1.11x
Debt / EBITDA	2.84x	3.55x	4.45x	4.62x	5.05x	2.45x	2.54x	2.58x	1.66x	2.15x
Net Debt / EBITDA	2.21x	3.02x	3.76x	3.55x	4.16x	2.01x	2.13x	2.02x	1.34x	1.34x
Interest Coverage	5.81x	7.39x	7.79x	6.75x	5.57x	7.54x	8.76x	6.26x	11.77x	11.75x
Total Equity	3.49B▲ 0%	3.67B▲ 5.2%	24.32B▲ 562.3%	28.44B▲ 17.0%	28.91B▲ 1.6%	10.1B▼ 65.1%	16.31B▲ 61.6%	13.09B▼ 19.8%	15.93B▲ 21.7%	22.97B▲ 0%
Equity Growth %	-29.7%	5.25%	562.27%	16.96%	1.63%	-65.07%	61.56%	-19.77%	21.72%	122.71%
Book Value per Share	1.77	1.85	12.12	14.11	17.83	4.94	7.94	6.32	15.48	11.28
Total Shareholders' Equity	-68M	4.36B	15.11B	19.94B	20.39B	10.6B	17.01B	13.67B	16.35B	23.54B
Common Stock	1.34B	1.34B	1.78B	1.84B	1.82B	1.35B	1.72B	1.35B	1.35B	1.78B
Retained Earnings	-6.48B	-2.14B	8.45B	11.76B	13.26B	4.36B	9.23B	7.8B	10.19B	15.28B
Treasury Stock	-400M	-161M	-178.84M	-266.56M	-37.92M	0	-367.14M	0	0	0
Accumulated OCI	598M	373M	849.16M	2.12B	869.56M	0	2.04B	0	0	1.86B
Minority Interest	3.56B	-688M	9.21B	8.5B	8.52B	-502M	-703.69M	-585M	-420.26M	-567.04M

GSK Cash Flow Statement

GSK plc (GSK) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	6.92B	8.42B	8.02B	8.44B	7.95B	8.16B	7.89B	6.55B	7.14B	7.14B
Operating CF Margin %	22.92%	27.32%	23.76%	34.66%	32.2%	27.83%	26.02%	20.89%	21.87%	-
Operating CF Growth %	6.48%	21.73%	-4.76%	5.25%	-5.79%	2.62%	-3.3%	-16.94%	8.99%	115.96%
Net Income	2.17B	4.05B	5.27B	5.1B	3.52B	5.49B	6.13B	2.95B	5.59B	6.4B
Depreciation & Amortization	2.98B	1.76B	3B	2.05B	2.12B	2.64B	2.85B	2.55B	3.7B	3.4B
Stock-Based Compensation	333M	360M	365M	337M	343M	0	0	344M	0	0
Deferred Taxes	1.5B	1.78B	-1.95B	0	0	-965.72M	-1.08B	0	0	0
Other Non-Cash Items	669M	717M	814M	-1.24B	584M	2.66B	1.05B	-1.38B	-1.53B	-129.43M
Working Capital Changes	-737M	-247M	531M	2.19B	1.39B	-1.67B	-1.06B	2.09B	-608.37M	-1.8B
Change in Receivables	-213M	-411M	-192M	-628M	-1.16B	-758.78M	-806.74M	340M	0	0
Change in Inventory	-461M	51M	300M	100M	51M	-331.35M	-527.05M	-294M	0	0
Change in Payables	11M	131M	263M	0	0	608.5M	-18.65M	0	0	0
Cash from Investing	-1.44B	-1.55B	-5.35B	2.16B	-1.78B	-10.88B	-2.4B	-1.23B	-5.72B	-6.6B
Capital Expenditures	-2.2B	-1.8B	-2.16B	-989M	-950M	-2.78B	-2.91B	-1.4B	-2.92B	-2.68B
CapEx % of Revenue	7.29%	5.83%	6.41%	4.06%	3.85%	9.48%	9.61%	4.46%	8.94%	-
Acquisitions	356M	-292M	-3.78B	2.85B	185M	-3.79B	-1.72B	1.37B	-4.37B	-5.09B
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	395M	1.3B	846M	-2.97B	-1.03B	-4.43B	14.92M	-1.22B	1.46B	996.88M
Cash from Financing	-6.38B	-6.39B	-1.84B	-10.13B	-7.59B	2.05B	-6.07B	-4.73B	-1.59B	-3B
Debt Issued (Net)	-990M	8.15B	3.73B	-4.03B	-2B	-5.69B	-2.95B	-1.17B	1.47B	141.62M
Equity Issued (Net)	-9M	74M	51M	29M	21M	30.79M	12.43M	20M	14.67M	-1.33B
Dividends Paid	-3.91B	-3.93B	-3.95B	-3.98B	-4B	-4.27B	-2.79B	-2.44B	-2.51B	-2.83B
Share Repurchases	-65M	0	0	0	0	0	0	0	0	-1.34B
Other Financing	-1.48B	-10.69B	-1.67B	-2.15B	-1.61B	11.98B	-341.84M	-1.14B	-573.16M	1.02B
Net Change in Cash	-1B▲ 0%	487M▲ 148.5%	744M▲ 52.8%	431M▼ 42.1%	-1.44B▼ 434.8%	-1.31B▲ 9.2%	-735.58M▲ 43.9%	545M▲ 174.1%	-206.06M▼ 137.8%	-1.37B▲ 0%
Free Cash Flow	4.72B▲ 0%	6.63B▲ 40.5%	5.86B▼ 11.6%	6.5B▲ 10.9%	5.3B▼ 18.4%	6.75B▲ 27.5%	6.26B▼ 7.3%	3.57B▼ 42.9%	5.82B▲ 63.1%	7.37B▲ 0%
FCF Margin %	15.62%	21.5%	17.35%	26.67%	21.45%	23.03%	20.63%	11.38%	17.83%	22.11%
FCF Growth %	13.78%	40.48%	-11.59%	10.91%	-18.44%	27.46%	-7.33%	-42.92%	63.06%	58%
FCF per Share	2.39	3.33	2.92	3.22	3.27	3.31	3.04	1.72	5.66	5.66
FCF Conversion (FCF/Net Income)	4.52x	2.32x	1.73x	1.47x	1.81x	0.55x	1.60x	2.55x	1.25x	1.15x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

GSK Key Ratios

GSK plc (GSK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	36.25%	101.19%	33.19%	21.79%	15.29%	76.69%	37.32%	17.52%	39.4%	31.48%
Return on Invested Capital (ROIC)	17.22%	19.3%	12.38%	7.77%	5.79%	11.6%	16.09%	9.74%	22.1%	22.1%
Gross Margin	65.74%	66.77%	64.85%	67.44%	66.95%	67.42%	71.76%	71.16%	72.4%	72.86%
Net Margin	5.08%	11.76%	13.76%	23.61%	17.76%	51%	16.25%	8.21%	17.5%	19.19%
Debt / Equity	4.90x	7.10x	1.66x	1.30x	1.13x	2.08x	1.41x	1.30x	1.11x	1.11x
Interest Coverage	5.81x	7.39x	7.79x	6.75x	5.57x	7.54x	8.76x	6.26x	11.77x	11.75x
FCF Conversion	4.52x	2.32x	1.73x	1.47x	1.81x	0.55x	1.60x	2.55x	1.25x	1.15x
Revenue Growth	8.24%	2.1%	9.52%	-27.85%	1.4%	18.74%	3.42%	3.46%	4.11%	5.41%

GSK Frequently Asked Questions

GSK plc (GSK) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

GSK plc (GSK) reported $33.34B in revenue for fiscal year 2025. This represents a 300% increase from $8.34B in 1996.

GSK plc (GSK) grew revenue by 4.1% over the past year. Growth has been modest.

Yes, GSK plc (GSK) is profitable, generating $6.40B in net income for fiscal year 2025 (17.5% net margin).

Dividend & Returns

Yes, GSK plc (GSK) pays a dividend with a yield of 6.57%. This makes it attractive for income-focused investors.

GSK plc (GSK) has a return on equity (ROE) of 39.4%. This is excellent, indicating efficient use of shareholder capital.

GSK plc (GSK) generated $7.37B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More GSK

GSK plc (GSK) financial analysis — history, returns, DCA and operating performance tools

Full GSK Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

GSK plc(GSK)Earnings, Financials & Key Ratios

GSK Key Insights

✓Strengths

✗Weaknesses

GSK Price & Volume

GSK Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

GSK Recent Earnings

GSK Peer Comparison

Compare GSK vs Peers

vs AZN

vs LLY

Compare Top 5

GSK Income Statement

GSK Balance Sheet

GSK Cash Flow Statement

GSK Key Ratios

GSK Frequently Asked Questions

Explore More GSK

Full GSK Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation